About Leiutis Pharmaceuticals LLP
Data last updated:
Leiutis Pharmaceuticals LLP is a limited liability partnership (LLP) based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 May 2021 and has been in existence for over 5 years.
The LLP is registered with the Registrar of Companies (ROC), Hyderabad, under LLPIN AAX-0501. Its GSTIN is 36AAJFL4690C1Z9 (Telangana).
The LLP has a total obligation of contribution of ₹6.9 Cr. It is led by designated partners including Manikreddy Pullagurla and Harcharan Singh.
Its latest statement of accounts is for the year ended 31 March 2025. The registered office is at Hyderabad, Telangana.
As per the financials filed for FY 2025, the LLP reported a revenue of ₹52.13 Cr, a decline of 39% compared to the previous year. For the same year it recorded a net profit of ₹16.73 Cr (net margin 32.1%) and EBITDA of ₹28.53 Cr (EBITDA margin 54.7%). Revenue has declined at a compounded annual rate (CAGR) of 18% over three years.
The LLP is associated with 1 brand: Leiutis.
For more details, the LLP can be reached via its website leiutis.com.
Company details
Contact details
Leiutis Pharmaceuticals LLP's registered office is in Hyderabad, Telangana.
- Registered AddressPlot No 23, Tie Phase – 1 Ida Balanagar, Hyderabad, Telangana, India – 500037
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Leiutis Pharmaceuticals operates one associated brand: Leiutis. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical innovation company developing nanotherapeutics for global therapeutic areas. | leiutis.com |
Financials of Leiutis Pharmaceuticals LLP
FY 2025 filings availableLeiutis Pharmaceuticals LLP reported revenue of ₹52.13 Cr (down 39% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 18% over three years, including a 39% fall in the latest year. EBITDA fell 59% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Statement of Account and Solvency | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Income and Expenditure | ||||
| Turnover | ||||
| Other Income | ||||
| Total Income | ||||
| Purchases and Direct Costs | ||||
| Personnel Expenses | ||||
| Administrative Expenses | ||||
| Interest | ||||
| Depreciation | ||||
| Total Expenses | ||||
| Profit Before Tax | ||||
| Tax | ||||
| Profit After Tax | ₹16.73 Cr | |||
| Profit Transferred to Partners | ||||
| Assets and Liabilities | ||||
| Partners' Contribution | ||||
| Reserves and Surplus | ||||
| Secured Loans | ||||
| Unsecured Loans | ||||
| Trade Payables | ||||
| Other Liabilities and Provisions | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Loans and Advances | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Statement of Account and Solvency | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| Net Profit Margin | 32.1% | |||
| Return on Partners' Funds | ||||
| Return on Assets | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Debt to Partners' Funds | ||||
| Interest Coverage | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Turnover Growth | ||||
| Profit Growth | ||||
To see the full financial statements and ratios of Leiutis Pharmaceuticals LLP, buy the company report.
Designated partners of Leiutis Pharmaceuticals LLP
Leiutis Pharmaceuticals has 6 current designated partners and 1 former designated partner. Current designated partners are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manikreddy Pullagurla Also directs: Vivere Imaging Private Limited, Biophore India Pharmaceuticals Private Limited, Ewings Ventures LLP and 5 more | Designated Partner | 17 May 2021 | 5 Years 5 Months | Current |
| Harcharan Singh | Designated Partner | 17 May 2021 | 5 Years 5 Months | Current |
| Chandra Shekhar Kocherlakota Also directs: Ewings Ventures LLP, Tervis Medical Systems Private Limited | Designated Partner | 17 May 2021 | 5 Years 5 Months | Current |
| Ramprasad Nimmagadda | Designated Partner | 17 May 2021 | 5 Years 5 Months | Current |
| Madhusudana Rao Kothapalli | Designated Partner | 17 May 2021 | 5 Years 5 Months | Current |
| Jagadeesh Babu Rangisetty Also directs: Vivere Imaging Private Limited, Biophore India Pharmaceuticals Private Limited, Ewings Ventures LLP and 5 more | Designated Partner | 17 May 2021 | 5 Years 5 Months | Current |
Peer comparison
Leiutis Pharmaceuticals LLP is compared with the 10 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Glacier Pharmaceuticals Private Limited | ₹54.81 Cr (FY 2025) | 3.0% | Amaravati, Maharashtra, India | |||
| KRS Pharmaceuticals Private Limited | ₹54.79 Cr (FY 2025) | 60.0% | Hyderabad, Telangana, India | |||
| Akriti Pharmaceuticals Private Limited | ₹53.84 Cr (FY 2025) | 12.0% | Thane, Maharashtra, India | |||
| Synchem Pharmaceuticals Private Limited | ₹53.59 Cr (FY 2025) | 4.0% | Indore, Madhya Pradesh, India | |||
| Suboneyo Chemicals and Pharmaceuticals Private Limited | ₹52.16 Cr (FY 2025) | 20.0% | Jalgaon, Maharashtra, India | |||
| Leiutis Pharmaceuticals LLPthis company | ₹52.13 Cr (FY 2025) | ₹16.73 Cr | 32.1% | -39.0% | Hyderabad, Telangana, India | |
| Intracin Pharmaceuticals Private Limited | ₹52.07 Cr (FY 2024) | 39.0% | Nadiad, Gujarat, India | |||
| MMC Pharmaceuticals Limited | ₹52.03 Cr (FY 2024) | -8.0% | Chennai, Tamil Nadu, India | |||
| Unilab Chemicals and Pharmaceuticals Private Limited | ₹51.94 Cr (FY 2024) | 5.0% | Mumbai, Maharashtra, India | |||
| Ranq Pharmaceuticals and Excipients Private Limited | ₹51.83 Cr (FY 2025) | 5.0% | Thane, Maharashtra, India | |||
| Nutron Pharmaceuticals Private Limited | ₹51.48 Cr (FY 2025) | 1.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Leiutis Pharmaceuticals LLP, buy the company report.
Legal cases
No court or tribunal cases involving Leiutis Pharmaceuticals LLP are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Leiutis Pharmaceuticals LLP; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Leiutis Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAJFL4690C1Z9 | Telangana | Active | 17 Aug 2021 |
To see the full GST registrations and return filing status of Leiutis Pharmaceuticals LLP, buy the company report.
Recent activity
Leiutis Pharmaceuticals LLP has 7 designated partner changes on record since 2021: 7 appointments. The latest: Chandra Shekhar Kocherlakota was appointed as Designated Partner on 17 May 2021.
Frequently asked questions
Leiutis Pharmaceuticals is an active limited liability partnership based in Hyderabad, Telangana, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 17 May 2021 (5+ years old) and is registered under LLPIN AAX-0501.
Leiutis Pharmaceuticals has 6 current designated partners:
- Manikreddy Pullagurla - Designated Partner
- Harcharan Singh - Designated Partner
- Chandra Shekhar Kocherlakota - Designated Partner
- Ramprasad Nimmagadda - Designated Partner
- Madhusudana Rao Kothapalli - Designated Partner
- Jagadeesh Babu Rangisetty - Designated Partner
The latest financial statements of Leiutis Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 31 March 2025. Year-wise statements from FY 2022 are in the company report.
The GSTIN of Leiutis Pharmaceuticals is 36AAJFL4690C1Z9, registered in Telangana.
The LLPIN (Limited Liability Partnership Identification Number) of Leiutis Pharmaceuticals is AAX-0501. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.
Leiutis Pharmaceuticals was incorporated on 17 May 2021, making it 5+ years old. It is registered with the Registrar of Companies, Hyderabad.
The peers of Leiutis Pharmaceuticals by revenue are Glacier Pharmaceuticals Private Limited, KRS Pharmaceuticals Private Limited, Akriti Pharmaceuticals Private Limited, Synchem Pharmaceuticals Private Limited, Suboneyo Chemicals and Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharmaceuticals).
Chandra Shekhar Kocherlakota was appointed as Designated Partner on 17 May 2021. Harcharan Singh was appointed as Designated Partner on 17 May 2021. Jagadeesh Babu Rangisetty was appointed as Designated Partner on 17 May 2021. Leiutis Pharmaceuticals has 7 designated partner changes on record in total.
Leiutis Pharmaceuticals can be reached through the website leiutis.com. Its registered office is in Hyderabad, Telangana, India.
The registered office of Leiutis Pharmaceuticals is at Plot No 23, Tie Phase – 1 Ida Balanagar, Hyderabad, Telangana, India – 500037.
Leiutis Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.